Extended Data Fig. 4: ORR by IL-8 subgroup across trials and treatment arms. | Nature Medicine

Extended Data Fig. 4: ORR by IL-8 subgroup across trials and treatment arms.

From: Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Extended Data Fig. 4

ORR vs baseline serum IL-8 levels <23 pg/ml or ≥23 pg/ml across treatment arms in CheckMate 067 (Mel), CheckMate 025 (RCC), CheckMate 017 (sqNSCLC), and CheckMate 057 (nsqNSCLC). IL, interleukin; Mel, melanoma; nsqNSCLC, nonsquamous non-small cell lung cancer; ORR, objective response rate; RCC, renal cell carcinoma; sqNSCLC, squamous NSCLC. aPatients with complete response or partial response per RECIST v1.1.

Back to article page